Published in Br J Haematol on April 07, 2011
Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (1995) 17.76
The p38 signal transduction pathway: activation and function. Cell Signal (2000) 6.18
Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem (1996) 5.42
Mitogen-activated protein kinases in apoptosis regulation. Oncogene (2004) 4.76
Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science (2002) 4.26
Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet (2004) 3.89
p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell (2007) 3.55
MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell (2005) 3.48
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
p38 MAP kinases: beyond the stress response. Trends Biochem Sci (2000) 3.20
p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet (2007) 3.19
Chronic lymphocytic leukaemia. Lancet (2008) 2.59
Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev (2000) 2.21
The pathways to tumor suppression via route p38. Trends Biochem Sci (2007) 2.15
p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med (2004) 1.74
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2007) 1.69
BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med (2003) 1.67
p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res (2004) 1.64
p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle (2007) 1.57
Cell cycle regulation by p38 MAP kinases. Biol Cell (2001) 1.44
Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene (2003) 1.41
p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Mol Biol Cell (2003) 1.37
FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Res (2008) 1.31
Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene (2005) 1.12
Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem (2004) 0.98
A radical role for p38 MAPK in tumor initiation. Cancer Cell (2007) 0.97
Differential activation of c-Jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway. J Immunol (1999) 0.95
Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism. Leuk Lymphoma (2003) 0.95
p38 MAP kinase mediates arsenite-induced apoptosis through FOXO3a activation and induction of Bim transcription. Apoptosis (2008) 0.93
Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. Br J Haematol (2005) 0.92
Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction. Apoptosis (2007) 0.89
Pathway-specific apoptotic gene expression profiling in chronic lymphocytic leukemia and follicular lymphoma. Mod Pathol (2006) 0.85
Chronic lymphocytic leukaemia: a short overview. Ann Oncol (2008) 0.85
Mitogen-activated protein kinases mediate arsenic-induced down-regulation of survivin in human lung adenocarcinoma cells. Arch Toxicol (2005) 0.84
ERK 1,2 and p38 pathways are involved in the proliferative stimuli mediated by urokinase in osteoblastic SaOS-2 cell line. J Cell Biochem (2001) 0.82
Influence of controllable lifestyle on recent trends in specialty choice by US medical students. JAMA (2003) 14.06
Detection of microRNA expression in human peripheral blood microvesicles. PLoS One (2008) 8.04
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (2011) 5.98
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med (2014) 4.98
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood (2010) 4.69
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood (2013) 4.17
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology (2014) 3.92
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 3.89
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A (2010) 3.86
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem (2009) 3.71
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell (2007) 3.58
Adult Burkitt leukemia and lymphoma. Blood (2004) 3.46
The influence of controllable lifestyle and sex on the specialty choices of graduating U.S. medical students, 1996-2003. Acad Med (2005) 3.32
Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood (2014) 2.94
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest (2007) 2.91
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol (2008) 2.79
Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches. Oncology (Williston Park) (2012) 2.73
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol (2007) 2.64
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2010) 2.45
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 2.41
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood (2009) 2.39
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood (2004) 2.39
The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood (2012) 2.39
Administrative coding data, compared with CDC/NHSN criteria, are poor indicators of health care-associated infections. Am J Infect Control (2008) 2.38
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell (2010) 2.37
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol (2012) 2.36
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol (2009) 2.34
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood (2012) 2.27
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol (2011) 2.26
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood (2008) 2.22
E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature (2009) 2.22
Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst (2002) 2.22
From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res (2004) 2.19
Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. Blood (2009) 2.17
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clin Cancer Res (2005) 2.10
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J (2007) 2.08
17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood (2010) 2.07
Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem (2005) 2.06
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma (2009) 2.06
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood (2013) 2.03
Atypical lymphocytic lobular panniculitis. J Cutan Pathol (2004) 2.02
Discovery of anticancer agents of diverse natural origin. Pure Appl Chem (2009) 2.00
miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res (2010) 1.99
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood (2012) 1.97
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood (2006) 1.92
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood (2009) 1.83
A comparison of normalization techniques for microRNA microarray data. Stat Appl Genet Mol Biol (2008) 1.82
Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J (2005) 1.80
Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res (2007) 1.75
Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 1.73
Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst (2002) 1.73
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 1.72
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2007) 1.69
Rituximab-induced hepatitis C virus reactivation after spontaneous remission in diffuse large B-cell lymphoma. J Clin Oncol (2008) 1.69
Targeting histone deacetylase in cancer therapy. Med Res Rev (2006) 1.69
Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res (2005) 1.69
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol (2014) 1.65
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol (2011) 1.65